Liver fibrosis is the result of an exacerbated wound-healing response associated with chronic liver injury. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and frequently requires liver transplantation. The host immune response has an important role driving fibrosis deposition by activating hepatic stellate cells (HSCs). Interleukin-22 (IL-22) is a cytokine that plays a key role in promoting antimicrobial immunity and tissue repair at barrier surfaces. Data from literature suggest that IL-22 has a protective role in the liver by reducing fibrosis in some pathological conditions, however the results are contradictory. This review highlights current knowledge of IL-22' role in chronic liver injury, as well as its therapeutic potential for the treatment of chronic liver injury.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cyto.2016.08.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Application of Dorzagliatin in peritoneal dialysis patients with type 2 diabetes mellitus: A case report.
World J Diabetes
January 2025
Department of Endocrinology, Beijing Haidian Hospital, Beijing 100080, China.
Background: Treating diabetes in dialysis patients remains a challenge, with many hypoglycemic drugs requiring dose adjustments or avoidance in these patients.
Case Summary: This report describes an 83-year-old female patient with a 30-year history of type 2 diabetes (T2DM) who had struggled to control her blood sugar for more than a year. She had a history of high blood pressure for 30 years, had undergone continuous ambulatory peritoneal dialysis for more than two years, was 163 cm tall, weighed 77 kg, and had a body mass index of 28.
Lessons Learned From the Liver About the Undergraduate to Graduate Medical Education Transition.
Am J Med Open
June 2025
University of Illinois Chicago, Department of Gastroenterology and Hepatology, Chicago, IL, USA.
The burden of cirrhosis and chronic liver disease is growing, yet there is a projected worsening deficit in hepatology providers. As such, cirrhosis and liver disease have been important inclusions within the core curricula of Internal Medicine. Formal assessments of provider preparedness resulting from the curriculum are lacking though.
View Article and Find Full Text PDFConventional and Advanced Methods Used for the Diagnosis of Fascioliosis, a Food-Borne Zoonotic Disease.
J Parasitol Res
January 2025
Department of Parasitology, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Fascioliosis is a food-borne zoonotic helminth infection caused by flatworms belonging to the family Fasciolidae, primarily affecting ruminants. The chronic form of fascioliosis is the most prevalent and is characterized by anemia, weight loss, cirrhosis, and liver dysfunction, along with atrophy, jaundice, and bottle jaw. In humans, infection results in fever, nausea, skin rashes, and severe abdominal pain.
View Article and Find Full Text PDFAntioxidant and immunomodulatory activities of ethanol extracts from L. Skeels and Benth.
Narra J
December 2024
Department of Pharmacology-Clinical Pharmacy, School of Pharmacy, Institut Teknologi Bandung, Bandung, Indonesia.
and are mostly cultivated in tropical climates for culinary and perfumery purposes, yet their potential medicinal properties remain underreported. The aim of this study was to examine the antioxidant and immunomodulatory activities of ethanol extracts from (EESC) and (EEPC). Reflux extraction was carried out using 96% ethanol on the collected plant specimens to produce EESC and EEPC.
View Article and Find Full Text PDFImmunotherapy Using HBV Vaccine Pulsed DCs and Induced T-Cells Combined Antiviral Drugs in Treatment Naive CHB Patients-A Multi-Centre Phase II Study.
J Viral Hepat
February 2025
Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Dendritic cells are the most potent antigen-presenting cells in immune therapeutic approaches for chronic hepatitis B (CHB) infection. Here, we developed a clinical trial to evaluate the efficacy and safety of autologous HBV vaccine-pulsed DCs and their induced T cells (HPDCT) in CHB patients. This was a randomised, prospective, open-label, multicentre, superiority study and 309 treatment-naive CHB patients were divided into HPDCT plus nucleos(t)ide analogues (NAs) group (n = 84), NAs mono-therapy group (n = 82), HPDCT plus Peg-interferon (Peg-IFN) group (n = 69), Peg-IFN mono-therapy group (n = 74).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!